| Dr Amber Aria, OD | |
|
2900 Heartland Dr, Coralville, IA 52241-2740 | |
| (319) 545-3215 | |
| (319) 545-3214 |
| Full Name | Dr Amber Aria |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 2900 Heartland Dr, Coralville, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568610087 | NPI | - | NPPES |
| Provider Name | Myeyedr Optometry Of Florida, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073907028 PECOS PAC ID: 0143541037 Enrollment ID: O20150603002802 |
News Archive
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
A team of Johns Hopkins researchers developed a new radiotracer - a radioactive substance that can be traced in the body - to visualize and quantify the brain's cannabinoid receptors by positron emission tomography (PET).
"Though the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) has been touted as one of our nation's most successful initiatives in global health (and certainly one of President George W. Bush's most positive legacies) it continues to miss the mark" when it comes to family planning, global gender specialist and freelance writer Jessica Mack writes in KPLU 88.5's "Humanosphere" blog.
Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
› Verified 2 days ago
| Provider Name | Mobile Optix Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1346809480 PECOS PAC ID: 2567790785 Enrollment ID: O20190827001354 |
News Archive
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
A team of Johns Hopkins researchers developed a new radiotracer - a radioactive substance that can be traced in the body - to visualize and quantify the brain's cannabinoid receptors by positron emission tomography (PET).
"Though the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) has been touted as one of our nation's most successful initiatives in global health (and certainly one of President George W. Bush's most positive legacies) it continues to miss the mark" when it comes to family planning, global gender specialist and freelance writer Jessica Mack writes in KPLU 88.5's "Humanosphere" blog.
Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
› Verified 2 days ago
| Provider Name | Aeg Florida Professional Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1164156246 PECOS PAC ID: 3870960032 Enrollment ID: O20221101003017 |
News Archive
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
A team of Johns Hopkins researchers developed a new radiotracer - a radioactive substance that can be traced in the body - to visualize and quantify the brain's cannabinoid receptors by positron emission tomography (PET).
"Though the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) has been touted as one of our nation's most successful initiatives in global health (and certainly one of President George W. Bush's most positive legacies) it continues to miss the mark" when it comes to family planning, global gender specialist and freelance writer Jessica Mack writes in KPLU 88.5's "Humanosphere" blog.
Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amber Aria, OD 2900 Heartland Dr, Coralville, IA 52241-2740 Ph: (319) 545-3215 | Dr Amber Aria, OD 2900 Heartland Dr, Coralville, IA 52241-2740 Ph: (319) 545-3215 |
News Archive
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
A team of Johns Hopkins researchers developed a new radiotracer - a radioactive substance that can be traced in the body - to visualize and quantify the brain's cannabinoid receptors by positron emission tomography (PET).
"Though the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) has been touted as one of our nation's most successful initiatives in global health (and certainly one of President George W. Bush's most positive legacies) it continues to miss the mark" when it comes to family planning, global gender specialist and freelance writer Jessica Mack writes in KPLU 88.5's "Humanosphere" blog.
Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
› Verified 2 days ago
Roggy Vision Center, Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 708 5th St Ste 1, Coralville, IA 52241 Phone: 319-569-1936 | |
Dr. John Weihe, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1101 5th St, Suite 103, Coralville, IA 52241 Phone: 319-354-5030 | |
Cassidy Wendler, Optometrist Medicare: Medicare Enrolled Practice Location: 708 5th St Ste 1, Coralville, IA 52241 Phone: 319-569-1936 | |
Dr. Marlin Arthur Veatch, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2441 Coral Ct, Suite #5, Coralville, IA 52241 Phone: 319-665-2727 Fax: 877-335-3515 | |
Dr. Wayne Steven Huebener, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Vision 4 Less, 1810 N. Coral Street, Coralville, IA 52241 Phone: 319-246-5623 Fax: 319-351-2182 | |
Complete Vision Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1101 5th St, Suite 103, Coralville, IA 52241 Phone: 319-354-5030 Fax: 319-358-5806 | |
Ellingson Eyecare, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1451 Coral Ridge Ave Ste 518, Coralville, IA 52241 Phone: 319-466-0644 Fax: 319-466-0330 |